tbuckley/cabot-search huggingface dataset:
Corrigendum to ‘Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model’ [J Hepatol (2021) 1420-1433]
Authors: Taihua Yang, Marion Poenisch, Rajendra Khanal, Qingluan Hu, Zhen Dai, Ruomeng Li, Guangqi Song, Qinggong Yuan, Qunyan Yao, Xizhong Shen, Richard Taubert, Bastian Engel, Elmar Jaeckel, Arndt Vogel, Christine S. Falk, Axel Schambach, Daniela Gerovska, Marcos J. Araúzo-Bravo, Florian W.R. Vondran, Tobias Cantz, Nigel Horscroft, Asha Balakrishnan, Frédéric Chevessier, Michael Ott, Amar Deep Sharma
Journal: Journal of Hepatology (2022)
The potential of conditional cash transfers for the control of neglected tropical diseases
Authors: Dirk Engels, Thoko Elphick-Pooley
Journal: The Lancet Global Health (2022)

Neglected tropical diseases (NTDs) are a group of poverty-related diseases that particularly affect vulnerable communities in resource poor settings. Even though NTDs affect over 1·7 billion people globally, they have long been ignored in global and national health agendas and in budget allocations. To rectify such neglect, a global response was mounted in the early 2000s with the launch of the first WHO NTD road map and the London Declaration on NTDs whereby partners pledged strong support for its delivery.
TCTAP A-004 Acute Myocardial Infarction Cardiogenic Shock (AMICS) in Middle Eastern Patients, Insights From a 23-Years Registry
Authors: Ghiath Sadek Baroudy, Mohamed Salah Abdelghani, Abdul Rahman Arabi, Rajvir Singh, Jassim Al Suwaidi, Awad Alqahtani, Hajar Albinali
Journal: Journal of the American College of Cardiology (2022)
Centering Young People’s Perspectives, Needs, and Preferences in Researching Barriers to Medications for Opioid Use Disorder
Authors: Kirsten Marchand, Katrina Marie Pellatt, Skye Barbic
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers
Authors: Jenny W. Sun, Jessica G. Young, Aaron L. Sarvet, L. Charles Bailey, William J. Heerman, David M. Janicke, Pi-I Debby Lin, Sengwee Toh, Jason P. Block
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Anticonvulsant mood stabilizer treatment is associated with an increased risk of weight gain, but little is known about the risk of developing type 2 diabetes (T2D). <h3>Objective</h3> To evaluate the comparative safety of anticonvulsant mood stabilizers on risk of T2D in adults and children by emulating a target trial. <h3>Design, Setting, and Participants</h3> This observational cohort study used data from IBM MarketScan (2010-2019), with a 5-year follow-up period. The nationwide sample of US commercially insured patients included children (aged 10-19 years) and adults (aged 20-65 years) who initiated anticonvulsant mood stabilizer treatment. Data were analyzed from August 2020 to May 2021. <h3>Exposures</h3> Initiation and continuation of carbamazepine, lamotrigine, oxcarbazepine, or valproate. <h3>Main Outcomes and Measures</h3> Onset of T2D during follow-up. Weighted pooled logistic regression was used to estimate the association of initiation and continuation of carbamazepine, lamotrigine, oxcarbazepine, or valproate with the risk of developing T2D. Inverse probability weights were used to control for confounding and loss to follow-up by measured baseline and time-varying covariates. <h3>Results</h3> The analysis included 274 206 adults (159 428 women [58%]; mean [SD] age, 39.9 [13.2] years) and 74 005 children (38 672 girls [52%]; mean [SD] age, 15.6 [2.6] years) who initiated an anticonvulsant mood stabilizer. In adults, initiation of valproate was associated with an increased risk of developing T2D compared with initiation of lamotrigine (5-year risk difference [RD], 1.17%; 95% CI, 0.66% to 1.76%). The number needed to harm was 87 patients initiating valproate for 1 patient to develop T2D within 5 years compared with initiation of lamotrigine. Point estimates were similar when evaluating the association of treatment continuation (5-year RD, 1.99%; 95% CI, −0.64% to 5.31%). The estimated association was smaller and more variable comparing carbamazepine and oxcarbazepine to lamotrigine. In children, RDs were much smaller and more variable (5-year RD for initiation of oxcarbazepine vs lamotrigine, 0.29%; 95% CI, −0.12% to 0.69%; 5-year RD for initiation of valproate vs lamotrigine, 0.18%; 95% CI, −0.09% to 0.49%). <h3>Conclusions and Relevance</h3> In this cohort study, valproate was associated with the highest risk of developing T2D in adults. The comparative safety was generally similar in children, but estimates were small and variable. In the absence of randomized trials, emulating target trials within health care databases can generate the age-specific drug safety data needed to inform treatment decision-making.
Calcium burns beige
Authors: Jakub Bunk, Lawrence Kazak
Journal: The Journal of Experimental Medicine (2022)

In this issue of Journal of Experimental Medicine, Yin et al. (2022. J. Exp. Med.https://doi.org/10.1084/jem.20212491) discover that loss of FNIP1 is associated with browning of white adipose tissue, which they propose is driven by decreased calcium uptake into the ER.
Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A
Authors: P. Batty, A. M. Mo, D. Hurlbut, J. Ishida, B. Yates, C. Brown, L. Harpell, C. Hough, A. Pender, E. K. Rimmer, S. Sardo Infirri, A. Winterborn, S. Fong, D. Lillicrap
Journal: Blood (2022)
H3K27me3 conditions chemotolerance in triple-negative breast cancer
Authors: Justine Marsolier, Pacôme Prompsy, Adeline Durand, Anne-Marie Lyne, Camille Landragin, Amandine Trouchet, Sabrina Tenreira Bento, Almut Eisele, Sophie Foulon, Léa Baudre, Kevin Grosselin, Mylène Bohec, Sylvain Baulande, Ahmed Dahmani, Laura Sourd, Eric Letouzé, Anne-Vincent Salomon, Elisabetta Marangoni, Leïla Perié, Céline Vallot
Journal: Nature Genetics (2022)
Toward Ecologically Sustainable Mental Health Care—A Call for Action From Within Psychiatry
Authors: Jurjen J. Luykx, Helena T. S. Voetterl
Journal: JAMA Psychiatry (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway
Authors: Li-Shan Yan, Shuo-Feng Zhang, Gan Luo, Brian Chi-Yan Cheng, Chao Zhang, Yi-Wei Wang, Xin-Yu Qiu, Xiao-Hong Zhou, Qing-Gao Wang, Xue-Lan Song, Si-Yuan Pan, Yi Zhang
Journal: Metabolism (2022)
Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review
Authors: Alan G. Dawson, Kudzayi Kutywayo, Seid B. Mohammed, Dean A. Fennell, Apostolos Nakas
Journal: Thorax (2022)

Introduction Cytoreductive surgery has been used a part of multimodality treatment in patients with malignant pleural mesothelioma (MPM). The residual microscopic disease that remains will lead to disease progression in the majority of patients. Delivery of hyperthermic intrathoracic chemotherapy at the time of surgery has been used to address this microscopic disease, however it’s effect and place in the multimodality treatment sphere is unknown. The aim of this systematic review was to assess the effect of surgery and hyperthermic intrathoracic chemotherapy in patients with MPM on overall survival and disease-free interval. Methods Ovid MEDLINE, Embase, Web of Science and the Cochrane Database of Systematic Reviews were searched from database inception through to June 2021. Studies reporting overall survival and/or disease-free interval in patients with MPM undergoing cytoreductive surgery with hyperthermic intrathoracic chemotherapy were considered. Study quality was assessed using the Newcastle-Ottawa Scale. A narrative review was performed. Results Fifteen studies were eligible for inclusion comprising 598 patients. Surgery with hyperthermic intrathoracic chemotherapy was associated with a median overall survival and disease-free interval ranging from 11 to 75 months and 7.2 to 57 months, respectively. These appeared to be superior to patients not receiving hyperthermic intrathoracic chemotherapy (overall survival: 5–36 months and disease-free interval: 12.1–21 months). A higher dose of hyperthermic intrathoracic chemotherapy was associated with an improvement in overall survival compared with a lower dose: 18–31 months versus 6–18 months, respectively. The most common morbidity was atrial fibrillation followed by renal complications. Conclusion Surgery with hyperthermic intrathoracic chemotherapy offers a safe and effective therapy with an improvement in disease-free interval and overall survival, particularly when hyperthermic intrathoracic chemotherapy is administered at a higher dose. PROSPERO registration number CRD42019129002.
Mucosal suturing method after gastric endoscopic submucosal dissection using self-made transparent "cross-hood" attachment
Authors: Rindo Ishii, Ken Ohata, Bo Liu, Ryoju Negishi, Yohei Minato, Takashi Muramoto, Makoto Kobayashi
Journal: Endoscopy (2022)

The ulcer floor after endoscopic submucosal dissection (ESD) sometimes becomes so large that several defect closure techniques have been reported [1] [2] [3] [4] to prevent delayed bleeding or perforation. We developed a new device named the "cross-hood" that makes it easier to close a large mucosal defect after ESD.
Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data
Authors: Wei Wang, Yu-Jie Yang, Ri-Hong Zhang, Jing-Yu Deng, Zhe Sun, Sharvesh Raj Seeruttun, Zhen-Ning Wang, Hui-Mian Xu, Han Liang, Zhi-Wei Zhou
Journal: Military Medical Research (2022)

Abstract Background Currently, there is no formal consensus regarding a standard classification for gastric cancer (GC) patients with &lt; 16 retrieved lymph nodes (rLNs). Here, this study aimed to validate a practical lymph node (LN) staging strategy to homogenize the nodal classification of GC cohorts comprising of both &lt; 16 (Limited set) and ≥ 16 (Adequate set) rLNs. Methods All patients in this study underwent R0 gastrectomy. The overall survival (OS) difference between the Limited and Adequate set from a large Chinese multicenter dataset was analyzed. Using the 8th American Joint Committee on Cancer (AJCC) pathological nodal classification (pN) for GC as base, a modified nodal classification (N’) resembling similar analogy as the 8th AJCC pN classification was developed. The performance of the proposed and 8th AJCC GC subgroups was compared and validated using the Surveillance, Epidemiology, and End Results (SEER) dataset comprising of 10,208 multi-ethnic GC cases. Results Significant difference in OS between the Limited and Adequate set (corresponding N0–N3a) using the 8th AJCC system was observed but the OS of N0 limited vs. N1 adequate , N1 limited vs. N2 adequate , N2 limited vs. N3a adequate , and N3a limited vs. N3b adequate subgroups was almost similar in the Chinese dataset. Therefore, we formulated an N’ classification whereby only the nodal subgroups of the Limited set, except for pT1N0M0 cases as they underwent less extensive surgeries (D1 or D1 + gastrectomy), were re-classified to one higher nodal subgroup, while those of the Adequate set remained unchanged (N’0 = N0 adequate + pT1N0M0 limited , N’1 = N1 adequate + N0 limited (excluding pT1N0M0limited) , N’2 = N2 adequate + N1 limited , N’3a = N3a adequate + N2 limited , and N’3b = N3b adequate + N3a limited ). This N’ classification demonstrated less heterogeneity in OS between the Limited and Adequate subgroups. Further analyses demonstrated superior statistical performance of the pTN’M system over the 8th AJCC edition and was successfully validated using the SEER dataset. Conclusion The proposed nodal staging strategy was successfully validated in large multi-ethnic GC datasets and represents a practical approach for homogenizing the classification of GC cohorts comprising of patients with &lt; 16 and ≥ 16 rLNs.
TCTAP A-036 Annual Operator Volume Among Patients Treated Using Percutaneous Coronary Interventions With Rotational Atherectomy and Procedural Outcomes - Analysis Based on a Large National Registry
Authors: Rafał Januszek, Wojciech Wańha, Zbigniew Siudak, Krzysztof Malinowski, Wojciech Wojakowski, Krzysztof Reczuch, Sławomir Dobrzycki, Maciej Lesiak, Robert Gil, Adam Witkowski, Stanisław Bartuś
Journal: Journal of the American College of Cardiology (2022)
Computational Analysis of Routine Biopsies Improves Diagnosis and Prediction of Cardiac Allograft Vasculopathy
Authors: Eliot G. Peyster, Andrew Janowczyk, Abigail Swamidoss, Samhith Kethireddy, Michael D. Feldman, Kenneth B. Margulies
Journal: Circulation (2022)

Background: Cardiac allograft vasculopathy (CAV) is a leading cause of morbidity and mortality for heart transplant recipients. Although clinical risk factors for CAV have been established, no personalized prognostic test exists to confidently identify patients at high versus low risk of developing aggressive CAV. This investigation aimed to leverage computational methods for analyzing digital pathology images from routine endomyocardial biopsies (EMBs) to develop a precision medicine tool for predicting CAV years before overt clinical presentation. Methods: Clinical data from 1 year after transplant were collected on 302 transplant recipients from the University of Pennsylvania, including 53 patients with early-onset CAV and 249 no early-onset CAV controls. These data were used to generate a clinical model (Clinical Risk Factor Future Cardiac Allograft Vasculopathy Prediction Model [ClinCAV-Pr]) for predicting future CAV development. From this cohort, 183 archived EMBs were collected for CD31 and modified trichrome staining and then digitally scanned. These included 1-year posttransplant EMBs from 50 patients with early-onset CAV and 82 patients with no early-onset CAV, as well as 51 EMBs from disease control patients obtained at the time of definitive coronary angiography confirming CAV. Using biologically inspired, handcrafted features extracted from digitized EMBs, quantitative histological models for differentiating no early-onset CAV from disease controls (Histological Cardiac Allograft Vasculopathy Diagnostic Model [HistoCAV-Dx]) and for predicting future CAV from 1-year posttransplant EMBs were developed (Histological Future Cardiac Allograft Vasculopathy Prediction Model [HistoCAV-Pr]). The performance of histological and clinical models for predicting future CAV (ie, HistoCAV-Pr and ClinCAV-Pr, respectively) were compared in a held-out validation set before being combined to assess the added predictive value of an integrated predictive model (Integrated Histological/Clinical Risk Factor Future Cardiac Allograft Vasculopathy Prediction Model [iCAV-Pr]). Results: ClinCAV-Pr achieved modest performance on the independent test set, with an area under the receiver operating curve (AUROC) of 0.70. The HistoCAV-Dx model for diagnosing CAV achieved excellent discrimination, with an AUROC of 0.91, whereas the HistoCAV-Pr model for predicting CAV achieved good performance with an AUROC of 0.80. The integrated iCAV-Pr model achieved excellent predictive performance, with an AUROC of 0.93 on the held-out test set. Conclusions: Prediction of future CAV development is greatly improved by incorporation of computationally extracted histological features. These results suggest morphological details contained within regularly obtained biopsy tissue have the potential to enhance precision and personalization of treatment plans for patients after heart transplant.
Surgeons as Participants in the US Political System—A Call for Nuanced Analysis
Authors: Margaret C. Tracci
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
TCTAP C-139 Successful Bailout From Blow-Out Bleeding From Descending Branch of Left Lateral Circumflex Femoral Artery by Balloon Inflation via Trans-Radial R2P System and Polytetrafluoroethylene-Covered Viabahn Stent Placement via Ipsilateral RIKISHI, a Side-grooved Guiding Sheath, System After Successful Recanalization of Left Main Coronary Artery in a Patient With Post-cardiac Arrest Syndrome Under PCPS Support
Authors: Yuta Kikuchi, Tetsuya Ishikawa, Hideyuki Aoki, Hidehiko Nakamura, Kahoko Mori, Yuta Kimura, Tatsuhiko Ito, Tomoaki Ukaji, Kota Yamada, Yukiko Mizutani, Itaru Hisauchi, Shiro Nakahara, Yuji Itabashi, Sayuki Kobayashi, Isao Taguchi
Journal: Journal of the American College of Cardiology (2022)
The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma
Authors: Shufang Jin, Mingyu Li, Hanyue Chang, Ruijie Wang, Zhiyuan Zhang, Jianjun Zhang, Yue He, Hailong Ma
Journal: Molecular Cancer (2022)

N6-methyladenosine (m6A) RNA modification plays a critical role in various physiological and pathological conditions. However, the role of m6A modification in head and neck squamous cell carcinoma (HNSCC) remains elusive.In this study, the expression of m6A demethylases was detected by HNSCC tissue microarray. m6A-RNA immunoprecipitation (MeRIP) sequencing and RNA sequencing were used to identify downstream targets of ALKBH5. Comprehensive identification of RNA-binding proteins by mass spectrometry (ChIRP-MS) was used to explore the m6A "readers". Tumor-infiltrating lymphocytes were analyzed in SCC7-bearing xenografts in C3H mice.Here, we demonstrate the downregulation of m6A status and upregulation of two demethylases in HNSCC. Silencing the m6A demethylase alkB homolog 5, RNA demethylase (ALKBH5) suppresses tumor progression in vitro and in vivo. m6A-RNA immunoprecipitation sequencing reveals that ALKBH5 downregulates the m6A modification of DDX58 mRNA. Moreover, RIG-I, encoded by the DDX58 mRNA, reverses the protumorigenic characteristics of ALKBH5. ChIRP-MS demonstrates that HNRNPC binds to the m6A sites of DDX58 mRNA to promote its maturation. ALKBH5 overexpression inhibits RIG-I-mediated IFNα secretion through the IKKε/TBK1/IRF3 pathway. The number of tumor-infiltrating lymphocytes in C3H immunocompetent mice is reduced by ALKBH5 overexpression and restored by IFNα administration. Upregulation of AKLBH5 negatively correlates with RIG-I and IFNα expression in HNSCC patients.These findings unveil a novel mechanism of immune microenvironment regulation mediated by m6A modification through the ALKBH5/RIG-I/IFNα axis, providing a rationale for therapeutically targeting epitranscriptomic modulators in HNSCC.
TCTAP C-005 Conundrum of a ‘Primary’ Angioplasty: Provisional Stenting of Left Main Stem / Left Anterior Descending During STEMI With Double Bifurcation
Authors: Mohd Ridzuan Bin Mohd Said, Vijayendran Rajalingam, Anand Raj Silveraju, Kantha Rao Narasamuloo, Saravanan Krishinan, Chee Tat Liew, Dharmaraj Karthikesan
Journal: Journal of the American College of Cardiology (2022)